Preclinical Evidence versus Clinical Outcomes in CAR and Fc-CR T Cell Immunotherapy for Breast Cancer
Received Date: Oct 01, 2023 / Published Date: Oct 30, 2023
Abstract
Immunotherapy, specifically Chimeric Antigen Receptor (CAR) T cell and Fc-receptor-enhanced chimeric receptor (Fc-CR) T cell therapies, has emerged as a promising approach for treating cancer. The development and translation of these therapies from preclinical studies to clinical applications represent a critical phase in their evaluation. This abstract highlights the essential aspects of the relationship between preclinical evidence and clinical outcomes in CAR and Fc-CR T cell immunotherapy for cancer. In preclinical research, CAR and Fc-CR T cells have demonstrated impressive anti-tumor efficacy, targeting a wide range of tumor antigens. However, the translation of these findings into clinical practice has brought to light a series of challenges. Factors such as tumor microenvironment, patient heterogeneity, and safety concerns have influenced the clinical performance of these therapies, often leading to outcomes that differ from preclinical expectations. This abstract explores the critical components of preclinical evidence, including in vitro and animal model studies, and their implications on clinical outcomes. It examines the discordance between preclinical promise and clinical reality, shedding light on the factors that contribute to this discrepancy. Furthermore, we discuss the strategies and ongoing efforts to bridge the gap between preclinical and clinical results, emphasizing the need for improved predictive models and patient stratification. Understanding the complex relationship between preclinical evidence and clinical outcomes in CAR and Fc-CR T cell immunotherapy is essential for advancing the field and enhancing the effectiveness of these groundbreaking cancer treatments. By addressing the challenges and optimizing the translational process, researchers and clinicians can improve the prospects of delivering innovative, personalized, and more efficacious cancer immunotherapies to patients in the future
Citation: Arriga A (2023) Preclinical Evidence versus Clinical Outcomes in CARand Fc-CR T Cell Immunotherapy for Breast Cancer. Breast Can Curr Res 8: 218. Doi: 10.4172/2572-4118.1000218
Copyright: © 2023 Arriga A. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Tools
Article Usage
- Total views: 371
- [From(publication date): 0-2023 - Sep 01, 2024]
- Breakdown by view type
- HTML page views: 330
- PDF downloads: 41